Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-02-25
DOI
10.3389/fonc.2021.627612
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
- (2020) Z. Quandt et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review
- (2020) Michele Porcu et al. Targeted Oncology
- Diabetes mellitus induced by immune checkpoint inhibitors
- (2020) Zhenjiang Zheng et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Cases from the Immune‐Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade Induced Diabetes
- (2020) Alexia Zagouras et al. ONCOLOGIST
- Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
- (2020) Liang Wen et al. Frontiers in Immunology
- Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor
- (2019) Francesco Alessandrino et al. Abdominal Radiology
- Case of fulminant type 1 diabetes induced by the anti‐programmed death‐ligand 1 antibody, avelumab
- (2019) Yui Shibayama et al. Journal of Diabetes Investigation
- Acquired Lipodystrophy Associated with Nivolumab in a Patient with Advanced Renal Cell Carcinoma
- (2019) Camila Kruschewsky Falcao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma
- (2019) C. Sakaguchi et al. Current Oncology
- Acquired generalized lipodystrophy under immune checkpoint inhibition
- (2019) N. Haddad et al. BRITISH JOURNAL OF DERMATOLOGY
- T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors
- (2019) Sho Yoneda et al. DIABETES CARE
- Immune-related pancreatitis associated with checkpoint blockade in melanoma
- (2019) Johannes Kohlmann et al. MELANOMA RESEARCH
- Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis
- (2019) John George et al. PANCREATOLOGY
- Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event
- (2019) Mesut Yilmaz JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors
- (2019) Lucien Marchand et al. ACTA DIABETOLOGICA
- Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
- (2018) Marie-Léa Gauci et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC
- (2018) Nobuko Matsuura et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Anti–Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?
- (2018) Lucien Marchand et al. DIABETES CARE
- Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy
- (2018) Thiru Prasanna et al. Immunotherapy
- Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody
- (2018) Michiru Shiba et al. INTERNAL MEDICINE
- Programmed cell death-1 (PD-1) inhibitor induced type 1 diabetes mellitus: mini-review
- (2018) Katrien Clotman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma
- (2018) Akira Takahashi et al. MELANOMA RESEARCH
- Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab
- (2018) Kanako Sakurai et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
- (2018) Jordan J. Wright et al. DIABETES CARE
- Autoimmune pancreatitis after nivolumab anti–programmed death receptor-1 treatment
- (2018) Lea Dehghani et al. EUROPEAN JOURNAL OF CANCER
- Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient
- (2018) Sicheng Li et al. MEDICINE
- Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies
- (2017) Jean-Marie Michot et al. JOURNAL OF IMMUNOTHERAPY
- Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non–Small Cell Lung Cancer
- (2017) Giulia C. Leonardi et al. JOURNAL OF IMMUNOTHERAPY
- Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung Cancer
- (2017) Yuko Usui et al. Journal of Thoracic Oncology
- Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature
- (2017) Laura Hickmott et al. Targeted Oncology
- Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
- (2017) Pouyan N. Changizzadeh et al. Journal for ImmunoTherapy of Cancer
- Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
- (2017) James Luke Godwin et al. Journal for ImmunoTherapy of Cancer
- A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
- (2016) Elizabeth Hansen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
- (2016) Young Kwang Chae et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment
- (2016) Malik Asif Humayun et al. Hormones-International Journal of Endocrinology and Metabolism
- Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma
- (2016) Wataru Munakata et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient
- (2016) Yukiko Teramoto et al. JOURNAL OF DERMATOLOGY
- Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab
- (2016) Claire F. Friedman et al. JNCI-Journal of the National Cancer Institute
- Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
- (2016) Elisa González-Rodríguez et al. ONCOLOGIST
- Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
- (2016) Yuka Miyoshi et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy
- (2016) Masahide Okamoto et al. Journal of Diabetes Investigation
- Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab
- (2016) Claire F. Friedman et al. JNCI-Journal of the National Cancer Institute
- Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
- (2015) Juan Martin-Liberal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
- (2015) Mahnaz Mellati et al. DIABETES CARE
- Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
- (2015) Caroline Gaudy et al. DIABETES CARE
- Latent autoimmune diabetes of the adult: current knowledge and uncertainty
- (2015) E. Laugesen et al. DIABETIC MEDICINE
- Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes
- (2014) Nora M. Kochupurakkal et al. PLoS One
- Deficiency in B7-H1 (PD-L1)/PD-1 Coinhibition Triggers Pancreatic β-Cell Destruction by Insulin-Specific, Murine CD8 T-Cells
- (2010) Tarvo Rajasalu et al. DIABETES
- Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
- (2009) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now